Articles

Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Institute of Hematology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, Bologna, Italy
Medical Oncology Unit 2, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Department of Oncology and Hematology, Humanitas Cancer Center, Milano, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
Department of Oncology, Hematology and Respiratory Disease University of Modena and Reggio Emilia, Modena, Italy
Clinic of Hematology DISM, AOU SM Misericordia, Udine, Italy
Division of Hematology, IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
Clinic of Hematology, IRCSS Policlinico S. Matteo, Pavia, Italy
Medical Oncology Unit 2, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Department of Oncology and Hematology, Humanitas Cancer Center, Milano, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
Institute of Hematology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, Bologna, Italy
Institute of Hematology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, Bologna, Italy
Institute of Hematology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, Bologna, Italy
Vol. 98 No. 8 (2013): August, 2013 https://doi.org/10.3324/haematol.2012.083048